Investors of Aquestive Therapeutics Have Chance to Lead Securities Fraud Litigation

In a pressing legal development, the Rosen Law Firm, a well-established name in investor rights advocacy, has reminded individuals who purchased securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025, and January 8, 2026, about an imminent deadline. Investors have an opportunity to lead a class action lawsuit regarding allegations of securities fraud against the company. This announcement, made on March 27, 2026, sheds light on the legal recourse available to affected investors who may feel aggrieved by their investment decisions during the specified period.

Understanding the Class Action Lawsuit

The lawsuit represents a consolidated effort by those who purchased Aquestive securities during the class period. Investors may be entitled to compensation without incurring out-of-pocket fees due to the firm’s contingency fee structure. This means that the Rosen Law Firm operates on a "no win, no fee" basis, making it financially feasible for individual claims to be accurately represented without the burden of upfront costs.

Potential claimants are encouraged to take swift action as the deadline to move to serve as lead plaintiff is set for May 4, 2026. A lead plaintiff generally acts as a representative for other class members and can guide the direction of the litigation.

How to Get Involved

Interested investors can easily join the class action lawsuit by following the procedures outlined by the Rosen Law Firm. They can visit the firm’s website at Rosen Legal or reach out directly to attorney Phillip Kim via phone at 866-767-3653 or email at [email protected] for further information. It's noteworthy that a class action lawsuit has already been initiated, and affected investors have the opportunity to join this collective claim, asserting their rights against the company.

Insights into the Allegations

The basis of the lawsuit stems from claims that Aquestive Therapeutics made misleading statements and failed to disclose crucial information regarding its New Drug Application (NDA) for Anaphylm. This issue particularly revolves around the concealment of essential human factors involved in utilizing their sublingual film, specifically concerning packaging, administration, and labeling, which were not adequately communicated to investors. When the reality of the situation emerged, the lawsuit alleges that investors suffered significant financial losses.

Therefore, the class action is critical as it represents a unified front for shareholders seeking accountability from the company. Rosen Law Firm urges any investors who believe they may have been impacted to seek qualified legal counsel, emphasizing the importance of working with a capable firm that has a proven track record in handling such significant cases.

The Rosen Law Firm's Proven Track Record

Rosen Law Firm prides itself on being a leader in investor representation and has achieved notable milestones, including securing the largest settlement in securities class action history against a Chinese company. With a focus on securities class actions and shareholder derivative litigation, the firm has been consistently recognized for its effectiveness and success in recovering substantial funds for investors over the years. In 2019 alone, the firm recovered over $438 million for investors, highlighting its commitment and capabilities.

The firm also has a strong reputation among its peers; it has been ranked as the foremost firm in the number of class action settlements since 2013, with acknowledgments from various legal institutions such as Lawdragon and Super Lawyers.

Final Thoughts

The unfolding situation with Aquestive Therapeutics serves as a reminder of the importance of vigilance when it comes to investment decisions. For those affected, knowing your options and deadlines is crucial. Joining this lawsuit may not only provide potential restitution but also ensure accountability from the companies that hold investor trust. Interested parties should act promptly to ensure they do not miss the opportunity to participate in this significant legal action.

As developments progress in this case, the Rosen Law Firm will provide ongoing updates on various platforms, allowing all stakeholders to stay informed. This is a chance for investors to reclaim a sense of agency in the wake of disappointing disclosures and alleged misconduct from the companies they supported.